The bill requires that before any individual can serve as a special Government employee in a federal agency, the head of the agency must ensure the candidate undergoes a drug test in accordance with the Mandatory Guidelines for Federal Workplace Drug Testing Programs. Within 90 days after enactment, agencies must place any current special Government employees in a sensitive position into a random drug-testing program under the same guidelines.
A positive test triggers penalties: for prospective SGEs, ineligibility for appointment for at least 12 months; for current SGEs, removal from the civil service and ineligibility for appointment as an SGE for at least 12 months.
At a Glance
What It Does
Before service, the head of an agency must ensure a candidate for a special Government employee in a sensitive position undergoes a drug test under the Mandatory Guidelines. Within 90 days after enactment, agencies must enroll any current SGEs in a random testing program under the same guidelines. A positive result triggers disqualification or removal with at least 12 months of ineligibility.
Who It Affects
The bill directly affects prospective SGEs seeking appointment and current SGEs in sensitive positions, as well as agency heads and human resources offices tasked with implementing testing under federal guidelines.
Why It Matters
It establishes a uniform, federally governed standard for drug testing in high-trust roles, aiming to safeguard national security and agency operations by deterring impairment and ensuring accountability.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The act introduces a structured drug-testing regime for special Government employees (SGEs) serving in sensitive federal roles. It requires pre-service testing of anyone proposed to become an SGE, using the federal guidelines that govern workplace drug testing.
This creates a consistent baseline for evaluating potential SGEs before they enter service.
In addition, the bill requires agencies to place any current SGEs in sensitive positions into a random drug-testing program within 90 days of enactment. The random testing must be conducted under the same federally mandated guidelines, ensuring ongoing monitoring for impairment or substance misuse among those who have access to sensitive information or critical operations.
Consequences for testing positive are specified: prospective appointees would be ineligible for appointment for at least 12 months, while current SGEs who test positive would be removed from the civil service and would face at least 12 months of ineligibility for appointment as an SGE. The act defines key terms such as controlled substances, agency, sensitive position, and special Government employee to set scope and authority for implementation.
The Five Things You Need to Know
The bill requires pre-service drug testing for proposed SGEs in sensitive positions.
Within 90 days of enactment, current SGEs in sensitive roles must enter a random testing program.
A positive test makes a prospective appointee ineligible for at least 12 months.
A positive test leads to removal from the civil service for current SGEs and at least 12 months of ineligibility.
Definitions cover substances, agency scope, sensitive positions, and SGE status.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title
This section provides the act’s short title as the Drug Testing for Special Government Employees Act, establishing the formal name used for references and amendments.
Mandatory Drug Testing for SGEs in Sensitive Positions
This section requires pre-service drug testing for any individual proposed to serve as an SGE in a federal agency, conducted in accordance with the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It also requires the head of each agency to ensure that individuals in sensitive positions are enrolled in a random drug-testing program within 90 days of enactment, using the same guidelines.
Effect of Failing Drug Tests
This section sets consequences for negative test outcomes: prospective SGEs who test positive are ineligible for appointment for a minimum of 12 months. For current SGEs who test positive, the act mandates removal from the civil service and an ineligibility period of at least 12 months for future SGE appointments.
Definitions
This section defines key terms used in the act: 'controlled substance' as per the Controlled Substances Act; 'agency' to include the Executive Office of the President and the Office of Management and Budget; 'sensitive position' including roles with classified access or high-trust requirements; and 'special Government employee' as defined in 18 U.S.C. 202.
This bill is one of many.
Codify tracks hundreds of bills on Government across all five countries.
Explore Government in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Heads of agencies and federal human resources offices gain a clear framework for testing and removal decisions, reducing ambiguity during personnel actions.
- Prospective SGEs seeking appointment to sensitive roles gain a transparent, standards-based path to evaluation that aligns with federal guidelines.
- Agency security offices and risk-management teams benefit from a uniform process aligned to established testing standards, improving accountability and oversight.
Who Bears the Cost
- Agencies must implement and administer drug-testing programs, incurring administrative and laboratory costs.
- Current SGEs who test positive face removal and a 12-month ineligibility period, impacting career progression and earnings.
- Prospective and current SGEs may incur time and resource costs related to testing procedures, placement in programs, and potential delays in hiring or appointment.
Key Issues
The Core Tension
The central tension is between ensuring safety and security in high-trust roles and protecting individuals’ privacy and due process rights within a federally mandated testing regime.
The bill’s approach relies on the federal Mandatory Guidelines, which has implications for privacy, due process, and the accuracy of drug tests. While it creates a clear consequence framework for positive results, it does not spell out procedures for retesting, appeals, or exemptions for medical or religious considerations.
The scope hinges on defining ‘sensitive positions,’ which may affect how broadly the policy applies within agencies. Implementation will require agency-level coordination to integrate pre-service and random testing with existing human resources and security processes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.